{"id":3637,"date":"2025-04-07T09:20:41","date_gmt":"2025-04-07T07:20:41","guid":{"rendered":"https:\/\/invivo.partners\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/"},"modified":"2025-04-07T10:19:47","modified_gmt":"2025-04-07T08:19:47","slug":"invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio","status":"publish","type":"post","link":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/","title":{"rendered":"Invivo Partners s&#8217;uneix a Sofinnova Partners en Signadori Bio"},"content":{"rendered":"<p style=\"text-align: center;\"><strong data-start=\"195\" data-end=\"212\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-3652 size-full alignleft\" src=\"https:\/\/invivo.partners\/wp-content\/uploads\/2025\/04\/Signadori-Bio_200x200.jpg\" alt=\"\" width=\"200\" height=\"201\" srcset=\"https:\/\/invivo.partners\/wp-content\/uploads\/2025\/04\/Signadori-Bio_200x200.jpg 200w, https:\/\/invivo.partners\/wp-content\/uploads\/2025\/04\/Signadori-Bio_200x200-150x150.jpg 150w, https:\/\/invivo.partners\/wp-content\/uploads\/2025\/04\/Signadori-Bio_200x200-186x187.jpg 186w\" sizes=\"auto, (max-width: 200px) 100vw, 200px\" \/><\/strong><strong data-start=\"171\" data-end=\"188\">Signadori Bio<\/strong>, una empresa biotecnol\u00f2gica creada per <strong data-start=\"228\" data-end=\"250\">Sofinnova Partners<\/strong> i <strong data-start=\"253\" data-end=\"271\">Gustave Roussy<\/strong>, est\u00e0 desenvolupant una plataforma revolucion\u00e0ria de ter\u00e0pia cel\u00b7lular per a l\u2019oncologia.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"666\" data-end=\"941\">Barcelona, Espanya, [8\/4\/2025] \u2013 Invivo Partners ha anunciat avui la seva inversi\u00f3 en Signadori Bio, una empresa biotecnol\u00f2gica pionera fundada a trav\u00e9s d\u2019una col\u00b7laboraci\u00f3 entre Sofinnova Partners, Gustave Roussy i els fundadors cient\u00edfics el Dr. Jean-Luc Perfettini i la professora Nathalie Chaput.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"666\" data-end=\"941\">Signadori Bio \u00e9s una empresa biofarmac\u00e8utica en fase precl\u00ednica que est\u00e0 desenvolupant una innovadora plataforma de ter\u00e0pia cel\u00b7lular per transformar el tractament del c\u00e0ncer. La seva plataforma pr\u00f2pia prov\u00e9 de Gustave Roussy, un centre oncol\u00f2gic reconegut internacionalment.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"943\" data-end=\"1530\">Aquesta iniciativa compta amb el suport del fons d\u2019acceleraci\u00f3 biotecnol\u00f2gica de Sofinnova de 165 milions d\u2019euros, Biovelocita II, que es centra a impulsar ci\u00e8ncia innovadora a Europa.<br data-start=\"1131\" data-end=\"1134\" \/>\u201cAvan\u00e7ar les ter\u00e0pies cel\u00b7lulars des del descobriment fins als pacients requereix una gran experi\u00e8ncia, orientaci\u00f3 estrat\u00e8gica i l\u2019ecosistema adequat. L\u2019excel\u00b7lent traject\u00f2ria d\u2019Invivo Partners en ter\u00e0pia cel\u00b7lular ser\u00e0 clau per accelerar el creixement de l\u2019empresa i portar tractaments innovadors a la cl\u00ednica\u201d, ha destacat Matthieu Coutet, CEO de Signadori Bio i soci de Sofinnova Partners.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"1532\" data-end=\"1998\">Aquesta inversi\u00f3 estrat\u00e8gica refor\u00e7a el comprom\u00eds d\u2019Invivo amb el desenvolupament de ter\u00e0pies cel\u00b7lulars de nova generaci\u00f3 en oncologia i consolida el seu paper com a inversor clau en la innovaci\u00f3 biotecnol\u00f2gica en etapes inicials. Juntament amb Sofinnova Partners, un l\u00edder reconegut en inversi\u00f3 en ci\u00e8ncies de la vida, Invivo est\u00e0 donant forma activa al futur de les ter\u00e0pies avan\u00e7ades, donant suport a la ci\u00e8ncia transformadora des del seu inici fins a l\u2019impacte.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"2000\" data-end=\"2411\">\u201c\u00c9s un honor unir-me a Sofinnova Partners en aquesta ambiciosa iniciativa. La ci\u00e8ncia que sorgeix de Gustave Roussy exemplifica el tipus d\u2019innovaci\u00f3 que Invivo Partners va ser creada per impulsar: disruptiva, basada en dades i profundament arrelada a les necessitats cl\u00edniques. Estem encantats de donar suport a aquest nou cap\u00edtol de la innovaci\u00f3 en oncologia.\u201d<br data-start=\"2361\" data-end=\"2364\" \/>\u2014 Laura Rodr\u00edguez, s\u00f2cia d\u2019Invivo Partners.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"2418\" data-end=\"2443\"><strong data-start=\"2418\" data-end=\"2443\">Sobre Invivo Partners<\/strong><\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"2445\" data-end=\"3183\">Invivo Partners \u00e9s una firma de capital risc especialitzada en empreses de ci\u00e8ncies de la vida en fases inicials. Est\u00e0 gestionada per Luis Pareras, Albert Ferrer i Laura Rodr\u00edguez, amb inversions en 16 empreses i tres fons sota gesti\u00f3.<br data-start=\"2680\" data-end=\"2683\" \/>Recentment ha anunciat el seu tercer fons, amb l\u2019objectiu de recaptar 100 milions d\u2019euros per invertir en empreses emergents de ci\u00e8ncies de la vida situades a la intersecci\u00f3 de les ter\u00e0pies avan\u00e7ades, la biologia sint\u00e8tica i la intel\u00b7lig\u00e8ncia artificial.<br data-start=\"2937\" data-end=\"2940\" \/>Invivo Ventures III compta amb una majoria d\u2019inversors privats, amb el suport d\u2019inversors institucionals com el Fons Europeu d\u2019Inversions (EIF), Fond-ICO Next Tech, l\u2019Institut Catal\u00e0 de Finances i l\u2019Ajuntament de Barcelona.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"3185\" data-end=\"3251\">M\u00e9s informaci\u00f3: <a class=\"\" href=\"https:\/\/invivo.partners\" target=\"_blank\" rel=\"noopener\" data-start=\"3201\" data-end=\"3251\">invivo.partners<\/a><\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"3258\" data-end=\"3286\"><strong data-start=\"3258\" data-end=\"3286\">Sobre Sofinnova Partners<\/strong><\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"3288\" data-end=\"3670\">Sofinnova Partners \u00e9s una firma europea l\u00edder en capital risc especialitzada en ci\u00e8ncies de la vida, centrada en salut i sostenibilitat. Amb seu a Par\u00eds, Londres i Mil\u00e0, el seu equip reuneix coneixements cient\u00edfics, m\u00e8dics i empresarials.<br data-start=\"3526\" data-end=\"3529\" \/>\u00c9s una empresa molt activa en la creaci\u00f3 de companyies al llarg de tota la cadena de valor, des de la fase inicial fins a etapes m\u00e9s madures.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"3672\" data-end=\"3937\">Fundada el 1972, compta amb 50 anys d\u2019experi\u00e8ncia donant suport a m\u00e9s de 500 empreses i creant l\u00edders de mercat a escala global. Actualment, gestiona m\u00e9s de 4.000 milions d\u2019euros en actius.<br data-start=\"3861\" data-end=\"3864\" \/>M\u00e9s informaci\u00f3: <a class=\"\" href=\"http:\/\/www.sofinnovapartners.com\" target=\"_blank\" rel=\"noopener\" data-start=\"3880\" data-end=\"3937\">sofinnovapartners.com<\/a><\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"3944\" data-end=\"3968\"><strong data-start=\"3944\" data-end=\"3968\">Sobre Gustave Roussy<\/strong><\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"3970\" data-end=\"4263\">Classificat per la revista Newsweek com el principal centre oncol\u00f2gic d\u2019Europa i el quart del m\u00f3n, Gustave Roussy \u00e9s un centre de refer\u00e8ncia dedicat \u00edntegrament a pacients amb c\u00e0ncer. \u00c9s membre fundador del Paris-Saclay Cancer Cluster i \u00e9s una font d\u2019aven\u00e7os diagn\u00f2stics i terap\u00e8utics.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"4265\" data-end=\"4577\">At\u00e9n prop de 50.000 pacients a l\u2019any, incloent-hi 3.500 nens i adolescents. El seu enfocament integra recerca, atenci\u00f3 al pacient i doc\u00e8ncia. Est\u00e0 especialitzat en c\u00e0ncers rars i tumors complexos, i ofereix un tractament personalitzat que combina t\u00e8cniques m\u00e8diques avan\u00e7ades amb una atenci\u00f3 humana i integral.<\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"4579\" data-end=\"4789\">Amb dues seus (a Villejuif i Chevilly-Larue), compta amb 4.100 professionals. El 40% dels pacients estan inclosos en estudis cl\u00ednics.<br data-start=\"4712\" data-end=\"4715\" \/>M\u00e9s informaci\u00f3: <a class=\"\" href=\"https:\/\/www.gustaveroussy.fr\/en\" target=\"_blank\" rel=\"noopener\" data-start=\"4731\" data-end=\"4789\">www.gustaveroussy.fr<\/a><\/p>\n<p class=\"\" style=\"text-align: justify;\" data-start=\"4796\" data-end=\"4830\"><strong data-start=\"4796\" data-end=\"4830\">Sobre Gustave Roussy Transfert<\/strong><\/p>\n<p style=\"text-align: justify;\">Creada l\u2019any 2000, \u00e9s la filial de transfer\u00e8ncia tecnol\u00f2gica de Gustave Roussy. Les seves missions s\u00f3n: (1) crear i identificar innovacions generades pels equips de recerca de Gustave Roussy, (2) establir i supervisar col\u00b7laboracions traslacionals, i (3) donar suport i promocionar projectes emprenedors de l\u2019institut.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Signadori Bio, una empresa biotecnol\u00f2gica creada per Sofinnova Partners i Gustave Roussy, est\u00e0 desenvolupant una plataforma revolucion\u00e0ria de ter\u00e0pia cel\u00b7lular per a l\u2019oncologia. Barcelona, Espanya, [8\/4\/2025] \u2013 Invivo Partners ha anunciat avui la seva inversi\u00f3 en Signadori Bio, una empresa biotecnol\u00f2gica pionera fundada a trav\u00e9s d\u2019una col\u00b7laboraci\u00f3 entre Sofinnova Partners, Gustave Roussy i els fundadors<\/p>\n","protected":false},"author":5,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"inline_featured_image":false,"footnotes":""},"categories":[516],"tags":[],"class_list":["post-3637","post","type-post","status-publish","format-standard","hentry","category-noticias-ca"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v21.3 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Invivo Partners s&#039;uneix a Sofinnova Partners en Signadori Bio - Invivo Partners<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/\" \/>\n<meta property=\"og:locale\" content=\"ca_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Invivo Partners s&#039;uneix a Sofinnova Partners en Signadori Bio - Invivo Partners\" \/>\n<meta property=\"og:description\" content=\"Signadori Bio, una empresa biotecnol\u00f2gica creada per Sofinnova Partners i Gustave Roussy, est\u00e0 desenvolupant una plataforma revolucion\u00e0ria de ter\u00e0pia cel\u00b7lular per a l\u2019oncologia. Barcelona, Espanya, [8\/4\/2025] \u2013 Invivo Partners ha anunciat avui la seva inversi\u00f3 en Signadori Bio, una empresa biotecnol\u00f2gica pionera fundada a trav\u00e9s d\u2019una col\u00b7laboraci\u00f3 entre Sofinnova Partners, Gustave Roussy i els fundadors\" \/>\n<meta property=\"og:url\" content=\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/\" \/>\n<meta property=\"og:site_name\" content=\"Invivo Partners\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-07T07:20:41+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-07T08:19:47+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/invivo.partners\/wp-content\/uploads\/2025\/04\/Signadori-Bio_200x200.jpg\" \/>\n<meta name=\"author\" content=\"Bego\u00f1a Aguirre\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrit per\" \/>\n\t<meta name=\"twitter:data1\" content=\"Bego\u00f1a Aguirre\" \/>\n\t<meta name=\"twitter:label2\" content=\"Temps estimat de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minuts\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/\"},\"author\":{\"name\":\"Bego\u00f1a Aguirre\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\"},\"headline\":\"Invivo Partners s&#8217;uneix a Sofinnova Partners en Signadori Bio\",\"datePublished\":\"2025-04-07T07:20:41+00:00\",\"dateModified\":\"2025-04-07T08:19:47+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/\"},\"wordCount\":803,\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"articleSection\":[\"Noticias\"],\"inLanguage\":\"ca\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/\",\"url\":\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/\",\"name\":\"Invivo Partners s'uneix a Sofinnova Partners en Signadori Bio - Invivo Partners\",\"isPartOf\":{\"@id\":\"https:\/\/invivo.partners\/#website\"},\"datePublished\":\"2025-04-07T07:20:41+00:00\",\"dateModified\":\"2025-04-07T08:19:47+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/#breadcrumb\"},\"inLanguage\":\"ca\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/invivo.partners\/ca\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Invivo Partners s&#8217;uneix a Sofinnova Partners en Signadori Bio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/invivo.partners\/#website\",\"url\":\"https:\/\/invivo.partners\/\",\"name\":\"Invivo Capital\",\"description\":\"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.\",\"publisher\":{\"@id\":\"https:\/\/invivo.partners\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/invivo.partners\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"ca\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/invivo.partners\/#organization\",\"name\":\"Invivo Capital\",\"url\":\"https:\/\/invivo.partners\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\",\"url\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"contentUrl\":\"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg\",\"width\":1200,\"height\":630,\"caption\":\"Invivo Capital\"},\"image\":{\"@id\":\"https:\/\/invivo.partners\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee\",\"name\":\"Bego\u00f1a Aguirre\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"ca\",\"@id\":\"https:\/\/invivo.partners\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g\",\"caption\":\"Bego\u00f1a Aguirre\"},\"url\":\"https:\/\/invivo.partners\/ca\/author\/bego\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Invivo Partners s'uneix a Sofinnova Partners en Signadori Bio - Invivo Partners","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/","og_locale":"ca_ES","og_type":"article","og_title":"Invivo Partners s'uneix a Sofinnova Partners en Signadori Bio - Invivo Partners","og_description":"Signadori Bio, una empresa biotecnol\u00f2gica creada per Sofinnova Partners i Gustave Roussy, est\u00e0 desenvolupant una plataforma revolucion\u00e0ria de ter\u00e0pia cel\u00b7lular per a l\u2019oncologia. Barcelona, Espanya, [8\/4\/2025] \u2013 Invivo Partners ha anunciat avui la seva inversi\u00f3 en Signadori Bio, una empresa biotecnol\u00f2gica pionera fundada a trav\u00e9s d\u2019una col\u00b7laboraci\u00f3 entre Sofinnova Partners, Gustave Roussy i els fundadors","og_url":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/","og_site_name":"Invivo Partners","article_published_time":"2025-04-07T07:20:41+00:00","article_modified_time":"2025-04-07T08:19:47+00:00","og_image":[{"url":"https:\/\/invivo.partners\/wp-content\/uploads\/2025\/04\/Signadori-Bio_200x200.jpg"}],"author":"Bego\u00f1a Aguirre","twitter_card":"summary_large_image","twitter_misc":{"Escrit per":"Bego\u00f1a Aguirre","Temps estimat de lectura":"4 minuts"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/#article","isPartOf":{"@id":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/"},"author":{"name":"Bego\u00f1a Aguirre","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee"},"headline":"Invivo Partners s&#8217;uneix a Sofinnova Partners en Signadori Bio","datePublished":"2025-04-07T07:20:41+00:00","dateModified":"2025-04-07T08:19:47+00:00","mainEntityOfPage":{"@id":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/"},"wordCount":803,"publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"articleSection":["Noticias"],"inLanguage":"ca"},{"@type":"WebPage","@id":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/","url":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/","name":"Invivo Partners s'uneix a Sofinnova Partners en Signadori Bio - Invivo Partners","isPartOf":{"@id":"https:\/\/invivo.partners\/#website"},"datePublished":"2025-04-07T07:20:41+00:00","dateModified":"2025-04-07T08:19:47+00:00","breadcrumb":{"@id":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/#breadcrumb"},"inLanguage":"ca","potentialAction":[{"@type":"ReadAction","target":["https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/invivo.partners\/ca\/2025\/04\/07\/invivo-partners-se-une-a-sofinnova-partners-en-signadori-bio\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/invivo.partners\/ca\/"},{"@type":"ListItem","position":2,"name":"Invivo Partners s&#8217;uneix a Sofinnova Partners en Signadori Bio"}]},{"@type":"WebSite","@id":"https:\/\/invivo.partners\/#website","url":"https:\/\/invivo.partners\/","name":"Invivo Capital","description":"Somos un fondo de capital riesgo especializado en proyectos early-stage del sector salud.","publisher":{"@id":"https:\/\/invivo.partners\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/invivo.partners\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"ca"},{"@type":"Organization","@id":"https:\/\/invivo.partners\/#organization","name":"Invivo Capital","url":"https:\/\/invivo.partners\/","logo":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/","url":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","contentUrl":"http:\/\/invivo.partners\/wp-content\/uploads\/2020\/04\/InvivoCapital_Banner.jpg","width":1200,"height":630,"caption":"Invivo Capital"},"image":{"@id":"https:\/\/invivo.partners\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/invivo.partners\/#\/schema\/person\/1dd96371a3f6bd32a0a04f752b53f1ee","name":"Bego\u00f1a Aguirre","image":{"@type":"ImageObject","inLanguage":"ca","@id":"https:\/\/invivo.partners\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/460068a94be660c8b15fdf3032d7898737605cd317d277a63782d52d9fd88201?s=96&d=mm&r=g","caption":"Bego\u00f1a Aguirre"},"url":"https:\/\/invivo.partners\/ca\/author\/bego\/"}]}},"_links":{"self":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3637","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/users\/5"}],"replies":[{"embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/comments?post=3637"}],"version-history":[{"count":9,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3637\/revisions"}],"predecessor-version":[{"id":3663,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/posts\/3637\/revisions\/3663"}],"wp:attachment":[{"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/media?parent=3637"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/categories?post=3637"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/invivo.partners\/ca\/wp-json\/wp\/v2\/tags?post=3637"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}